

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-000436

Date: 13/11/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below

Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

-
Patients with acute myeloid leukaemia (AML)

1. How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

Azacitidine monotherapy - 1
Low dose cytarabine (LoDAC) monotherapy - 4
Venetoclax + azacitidine - 13
Venetoclax + LoDAC - 3
Ivosidenib - 0
Intensive chemotherapy-based regimen - 9
Other

2. How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

Azacitidine monotherapy - 0
Low dose cytarabine (LoDAC) monotherapy - 0
Venetoclax + azacitidine - 6
Venetoclax + LoDAC - 1
Ivosidenib - 0
Intensive chemotherapy-based regimen - 7
Other - 1

Note: this should only include patients who have started first-line treatment during the 6-month window

3. (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq? 100%

Patients with chronic lymphocytic leukaemia (CLL)

4. How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? - 7

Note: this should include patients who started treatment prior to the 6-month window

5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? - 0

Note: this should include only patients who have started treatment during the 6-month window

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust